Transmedics Group, Inc. (TMDX) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Transmedics Group, Inc. (TMDX) stock forecast summary
Our AI scores Transmedics Group, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Transmedics Group, Inc. is a mid-cap company with a market capitalization of $2.39B. It ranks number 5 by market capitalization among the 29 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast. Its ROE of 26.2% is the highest of the 16 peers that report one.
For TMDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 26.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TMDX included.
TMDX price chart and AI forecast
How TMDX ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Transmedics Group, Inc. (TMDX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | TMDX | Rank |
|---|---|---|
| Market Cap | $2.39B | 5/29 |
| P/E Ratio | 18.39x | 6/9 |
| P/B Ratio | 4.34x | 8/23 |
| EPS | $3.75 | – |
| Book Value/Share | $15.88 | – |
| Revenue/Share | $20.98 | – |
| FCF/Share | $1.29 | – |
Profitability & Margins
| Metric | TMDX | Rank |
|---|---|---|
| ROE | 26.2% | 1/16 |
| ROA | 9.5% | 3/19 |
| ROIC | 6.3% | 8/21 |
| Gross Margin | 58.6% | 13/26 |
| Operating Margin | 11.9% | 4/26 |
| Net Margin | 19.9% | 2/18 |
| EBT Margin | 10.1% | 5/26 |
| Tax Rate | -96.2% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | TMDX | Rank |
|---|---|---|
| Current Ratio | 4.53x | 8/28 |
| Quick Ratio | 4.15x | 7/27 |
| D/E Ratio | 1.76x | 7/24 |
| Financial Leverage | 2.76x | 7/24 |
| Interest Coverage | 2.0x | 7/28 |
| Working Capital | $540M | 4/27 |
Cash Flow
| Metric | TMDX | Rank |
|---|---|---|
| Operating Cash Flow | $112M | 6/28 |
| Free Cash Flow | $45M | 4/14 |
| Capital Spending | -$68M | 11/14 |
| OCF Growth YoY | -36.9% | 8/8 |
| FCF Growth YoY | -63.0% | 6/6 |
| FCF/Sales | 6.1% | 5/14 |
| CapEx/Sales | 9.3% | 1/14 |
Operational Efficiency
| Metric | TMDX | Rank |
|---|---|---|
| Asset Turnover | 0.48x | 16/18 |
| Receivables Turnover | 6.3x | 9/20 |
| Inventory Turnover | 5.2x | 4/26 |
| Fixed Assets Turnover | 1.9x | 19/20 |
| Days Sales Outstanding | 58 days | 12/20 |
| Days Inventory | 71 days | 23/26 |
| Payables Period | 12 days | 23/24 |
| Cash Conversion Cycle | 116 days | 10/19 |
Income Statement
| Metric | TMDX | Rank |
|---|---|---|
| Total Revenue | $728M | 4/19 |
| Operating Income | $86M | 6/28 |
| Net Income | $144M | 4/20 |
| R&D Expense | $106M | 3/27 |
| SG&A Expense | $234M | 5/25 |
| Cost of Goods Sold | $301M | 5/26 |
Dividend & Shareholder Information
| Metric | TMDX | Rank |
|---|---|---|
| Shares Outstanding | 35M | – |
| Net Income Growth | 57.4% | 1/5 |
| EPS Growth | 51.8% | 2/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $692M | 45.6% of assets |
| Cash & Short-term Investments | $511M | 33.7% of assets |
| Accounts Receivable | $115M | 7.6% of assets |
| Inventory | $58M | 3.8% of assets |
| Total Liabilities | $967M | 63.7% of assets |
| Short-term Debt | $143M | 9.4% of assets |
TMDX quarterly financials and insider trading
Transmedics Group, Inc. (TMDX) industry peers
Companies classified under the same SEC industry code as Transmedics Group, Inc. (Electromedical & Electrotherapeutic Apparatus): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| TMDX Transmedics Group, Inc. | $2.39B | |
| MDT Medtronic Plc | $134.10B | |
| LIVN Livanova Plc | $4.96B | |
| ITGR Integer Holdings Corp | $4.30B | |
| AXGN Axogen, Inc. | $2.99B | |
| CNMD Conmed Corp | $1.53B | |
| CBLL Ceribell, Inc. | $1.02B | |
| INMD Inmode Ltd. | $766M | |
| CV Capsovision, Inc | $310M | |
| ELMD Electromed, Inc. | $227M | |
| FOCL Edap Tms Sa | $125M | |
| STXS Stereotaxis, Inc. | $109M | |
| VANI Vivani Medical, Inc. | $94M | |
| OM Outset Medical, Inc. | $77M | |
| NRXS Neuraxis, Inc | $77M | |
| HYPR Hyperfine, Inc. | $73M | |
| ECOR Electrocore, Inc. | $65M | |
| POCI Precision Optics Corporation, Inc. | $54M | |
| POSC Positron Corp | $54M | |
| VASO Vaso Corp | $51M | |
| QTI Qt Imaging Holdings, Inc. | $30M | |
| ITOC Itonic Holdings Ltd | $12M | |
| IRIX Iridex Corp | $12M | |
| GTHP Guided Therapeutics Inc | $10M | |
| NDRA Endra Life Sciences Inc. | $8M | |
| ADMT Adm Tronics Unlimited, Inc. | $6M | |
| NUWE Nuwellis, Inc. | $2M | |
| ESMC Escalon Medical Corp | $1M | |
| NXL Nexalin Technology, Inc. | $1M | |
| YBGJ Yubo International Biotech Ltd | N/A |
Where TMDX sits on the market map
Transmedics Group, Inc. (TMDX) stock news
Loading...
Transmedics Group, Inc. (TMDX) stock forecast FAQ
What is the Transmedics Group, Inc. (TMDX) stock forecast?
Our AI scores Transmedics Group, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Transmedics Group, Inc. stock predictions?
For TMDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 26.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Transmedics Group, Inc. forecasts updated?
Transmedics Group, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Transmedics Group, Inc.'s industry peers?
30 issuers in our coverage, TMDX included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Livanova Plc (LIVN), Integer Holdings Corp (ITGR), Axogen, Inc. (AXGN), Conmed Corp (CNMD), Ceribell, Inc. (CBLL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.